SABS - SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
- SAB Biotherapeutics press release ( NASDAQ: SABS ): Q2 GAAP EPS of -$0.11 beats by $0.03 .
- Cash and cash equivalents were $16.6 million as of June 30, 2022, compared to $22.4 million on March 31, 2022, which was driven primarily by $0.7 million in further capital expansion and SAB’s second quarter cash operating loss of $5.1 million.
- Financial Guidance: Based on its current operating plans, SAB expects that its existing business plan, cash and cash equivalents, and anticipated cash flows as of June 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for the twelve months following the date our quarterly report on Form 10-Q was made available for issuance.
For further details see:
SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03